⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

February 16, 2024Open Access

Table S3 from Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach

Courtney R. Schott Amanda Koehne Leanne C. Sayles Elizabeth P. Young Cuyler Luck Katharine Yu Alex G. Lee Marcus R. Breese Stanley G. Leung Hang Xu Avanthi Tayi Shah Heng-Yi Liu Aviv Spillinger Inge H. Behroozfard Kieren D. Marini Phuong Dinh María V. Pons Ventura Emma N. Vanderboon Florette K. Hazard Soo‐Jin Cho Raffi S. Avedian David G. Mohler Melissa N. Zimel Rosanna Wustrack Christina Curtis Marina Sirota E. Alejandro Sweet‐Cordero

View Full Paper

Ask AI

Bookmark

Share

Abstract

Copy number and count data for tumor suppressor genes and oncogenes in primary tumors, PDXs, and PDX-derived cell lines

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Schott et al. (2024) studied this question.

synapsesocial.com/papers/68e78f4db6db643587700660 https://doi.org/10.1158/1078-0432.25232537.v1

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Table S3 from Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach2024
2Figure S1-S14, Table S1-S2 & S4-S6 from Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach2024
3Data from Osteosarcoma PDX-Derived Cell Line Models for Preclinical Drug Evaluation Demonstrate Metastasis Inhibition by Dinaciclib through a Genome-Targeted Approach2024
4Supplementary Figure S4 from Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer2024
5Supplementary Figure S4 from Selective CDK7 Inhibition Suppresses Cell Cycle Progression and MYC Signaling While Enhancing Apoptosis in Therapy-resistant Estrogen Receptor–positive Breast Cancer2024

More related papers

Data from Pan-cancer pharmacogenomic analysis of patient-derived tumor cells utilizing clinically relevant drug exposures2024
Table S3 from A transcriptome-based precision oncology platform for patient-therapy alignment in a diverse set of treatment resistant malignancies2024
Table S1 from Paradoxical Activation of Oncogenic Signaling as a Cancer Treatment Strategy2024